第一单位：
Molecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, 08908, Spain.
作者：
Laura,Devis-Jauregui [1]
;
August,Vidal [2]
;
Laura,Plata-Peña [1]
;
Maria,Santacana [3]
;
Sandra,García-Mulero [4]
;
Nuria,Bonifaci [5]
;
Eulàlia,Noguera-Delgado [1]
;
Nuria,Ruiz [2]
;
Marta,Gil [6]
;
Eduard,Dorca [2]
;
Francisco J,Llobet [1]
;
Laura,Coll-Iglesias [1]
;
Katja,Gassner [7]
;
Maria,Martinez-Iniesta [8]
;
Ruth,Rodriguez-Barrueco [9]
;
Marc,Barahona [10]
;
Lola,Marti [10]
;
Francesc,Viñals [11]
;
Jordi,Ponce [10]
;
Rebeca,Sanz-Pamplona [4]
;
Josep M,Piulats [12]
;
Ana,Vivancos [13]
;
Xavier,Matias-Guiu [14]
;
Alberto,Villanueva [15]
;
David,Llobet-Navas [7]
作者单位：
Molecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, 08908, Spain.
[1]
Department of Pathology, University Hospital of Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, 08908, Spain.
[2]
Scientific and Technical Service of Immunohistochemistry, Lleida Institute for Biomedical Research Dr. Pifarré Foundation, IRBLleida, Hospital Universitari Arnau de Vilanova, Lleida, 25198, Spain.;Department of Pathology, Universitat de Lleida/Institut de Recerca Biomèdica de Lleida/Hospital Universitari Arnau de Vilanova, Lleida, 25198, Spain.
[3]
Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL) and CIBERESP, L'Hospitalet de Llobregat, Barcelona, 08908, Spain.
[4]
Department of Basic Sciences, Universitat de Lleida/Institut de Recerca Biomèdica de Lleida, Edifici Biomedicina I, Lab 2.4, Lleida, 25198, Spain.;Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, (ISCIII), Madrid, 28029, Spain.
[5]
Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat Barcelona, Barcelona, 08908, Spain.
[6]
Molecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, 08908, Spain.;Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, (ISCIII), Madrid, 28029, Spain.
[7]
Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, 08908, Spain.
[8]
Molecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, 08908, Spain.;Anatomy Unit, Department of Pathology and Experimental Therapy, School of Medicine, University of Barcelona (UB), L'Hospitalet de Llobregat, Barcelona, 08907, Spain.
[9]
Department of Gynaecology, University Hospital of Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, 08908, Spain.
[10]
Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, 08908, Spain.;Department of Physiological Sciences, School of Medicine, University of Barcelona (UB), L'Hospitalet de Llobregat, Barcelona, 08907, Spain.
[11]
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, (ISCIII), Madrid, 28029, Spain.;Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat Barcelona, Barcelona, 08908, Spain.
[12]
Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, 08035, Spain.
[13]
Molecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, 08908, Spain.;Department of Pathology, University Hospital of Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, 08908, Spain.;Scientific and Technical Service of Immunohistochemistry, Lleida Institute for Biomedical Research Dr. Pifarré Foundation, IRBLleida, Hospital Universitari Arnau de Vilanova, Lleida, 25198, Spain.;Department of Pathology, Universitat de Lleida/Institut de Recerca Biomèdica de Lleida/Hospital Universitari Arnau de Vilanova, Lleida, 25198, Spain.;Department of Basic Sciences, Universitat de Lleida/Institut de Recerca Biomèdica de Lleida, Edifici Biomedicina I, Lab 2.4, Lleida, 25198, Spain.;Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, (ISCIII), Madrid, 28029, Spain.
[14]
Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, 08908, Spain.;Xenopat S.L., Parc Cientific de Barcelona (PCB), Barcelona, 08028, Spain.
[15]
DOI
10.1002/advs.202204211
PMID
36373729
发布时间
2024-09-10
换一批
